Q1 Earnings Forecast for Belite Bio Issued By HC Wainwright

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) – Equities researchers at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Belite Bio in a research report issued on Thursday, May 21st. HC Wainwright analyst Y. Chen expects that the company will post earnings of $3.72 per share for the quarter. HC Wainwright has a “Buy” rating and a $200.00 price target on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($2.20) per share. HC Wainwright also issued estimates for Belite Bio’s Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at $0.53 EPS and Q4 2027 earnings at $2.02 EPS.

Several other brokerages also recently commented on BLTE. Cantor Fitzgerald lifted their target price on shares of Belite Bio from $200.00 to $266.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 3rd. Benchmark reaffirmed a “buy” rating on shares of Belite Bio in a research note on Tuesday, March 3rd. Bank of America assumed coverage on shares of Belite Bio in a research note on Monday, January 26th. They issued a “buy” rating and a $195.00 target price on the stock. Morgan Stanley lifted their target price on shares of Belite Bio from $191.00 to $201.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 3rd. Finally, Mizuho set a $223.00 target price on shares of Belite Bio in a research note on Thursday, February 19th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $202.33.

Belite Bio Stock Performance

Shares of BLTE stock opened at $144.25 on Friday. Belite Bio has a fifty-two week low of $56.10 and a fifty-two week high of $200.00. The stock has a 50 day moving average price of $159.99 and a two-hundred day moving average price of $156.74. The company has a market capitalization of $5.76 billion, a P/E ratio of -57.02 and a beta of -1.19.

Belite Bio (NASDAQ:BLTE) last released its earnings results on Wednesday, May 20th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.26.

Hedge Funds Weigh In On Belite Bio

A number of institutional investors have recently added to or reduced their stakes in the company. Darwin Global Management Ltd. bought a new position in Belite Bio in the fourth quarter worth $486,915,000. RA Capital Management L.P. bought a new position in Belite Bio in the third quarter worth $64,750,000. RTW Investments LP raised its holdings in Belite Bio by 128.9% in the fourth quarter. RTW Investments LP now owns 715,332 shares of the company’s stock worth $114,425,000 after purchasing an additional 402,832 shares in the last quarter. Millennium Management LLC raised its holdings in Belite Bio by 2,594.6% in the fourth quarter. Millennium Management LLC now owns 558,882 shares of the company’s stock worth $89,399,000 after purchasing an additional 538,141 shares in the last quarter. Finally, Perceptive Advisors LLC raised its holdings in Belite Bio by 732.0% in the fourth quarter. Perceptive Advisors LLC now owns 414,239 shares of the company’s stock worth $66,262,000 after purchasing an additional 364,451 shares in the last quarter. Institutional investors own 0.53% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Hao-Yuan Chuang sold 6,200 shares of the company’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $181.50, for a total transaction of $1,125,300.00. Following the completion of the transaction, the chief financial officer owned 93,800 shares in the company, valued at $17,024,700. This represents a 6.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Nathan L. Mata sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $155.78, for a total value of $155,780.00. Following the transaction, the insider owned 3,666 shares of the company’s stock, valued at approximately $571,089.48. This represents a 21.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 26,166 shares of company stock worth $4,548,351 in the last ninety days. Insiders own 13.29% of the company’s stock.

Belite Bio Company Profile

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.